The Conference Forum 2022 Webinar


Erin Newburn, MS PhD
December 8, 2022 | 12:00 noon ET

Presentation Title: A Next-Generation Liquid Biopsy Providing A Better Look at Residual Cancer

Minimal residual disease has emerged as a key biomarker in therapy development and patient care as researchers must find ways to monitor for residual cancer in patients after surgical or therapeutic treatment.

In this webinar, Dr Erin Newburn, Sr Director, Field Applications Scientist at Personalis, Inc, will walk the audience through a next-generation liquid biopsy that can identify evidence of post-treatment cancer cells. Providing high levels of sensitivity to test for residual disease, this test is unique in that it can also delineate potential treatment options.

This webinar will be of interest to pharma and biotech translational researchers who are developing drugs to combat cancer.

Attendees will learn about:

  • The role of next-generation liquid biopsy assays in enabling much earlier detection of disease recurrence
  • The utility of such biopsies in more disease indications and in earlier stages
  • Liquid biopsy’s role in patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials